|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,050 GBX | -0.87% |
|
+0.52% | +13.68% |
| May. 03 | Angle shares up on assay development deal with AstraZeneca | AN |
| May. 03 | Angle shares up on assay development deal with AstraZenaca | AN |
(Reuters) - AstraZeneca reported quarterly revenue and profit above market estimates on Thursday, buoyed by resilient demand for its oncology and rare blood disorder drugs.
The London-listed drugmaker reported core earnings per share of $2.06 on total revenue of $12.68 billion for the first quarter.
Analysts were expecting a core profit of $1.92 per share on revenue of $11.84 billion, according to a company-compiled consensus.
(Reporting by Eva Mathews in Bengaluru; Editing by Subhranshu Sahu)
| 1st Jan change | Capi. | |
|---|---|---|
| +13.68% | 234B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B | |
| +1.72% | 123B |
ASTRAZENECA PLC 
